LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report.

    Imoto, Waki / Himura, Hoshi / Matsuo, Kenji / Kawata, Sae / Kiritoshi, Ayako / Deguchi, Ryo / Miyashita, Masahiro / Kaga, Shinichiro / Noda, Tomohiro / Yamamoto, Katsumi / Yamada, Koichi / Uchida, Kenichiro / Nishimura, Tetsuro / Yamamoto, Hiromasa / Mizobata, Yasumitsu / Kakeya, Hiroshi

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

    2021  Volume 27, Issue 6, Page(s) 911–914

    Abstract: CAPA (COVID-19 associated pulmonary aspergillosis) is an important complication of COVID-19. It has ... been reported in Japan. A 72-year-old Japanese man was diagnosed with COVID-19 and was transferred ... deteriorated and he died. High-risk COVID-19 patients should be tested for Aspergillus to ensure ...

    Abstract CAPA (COVID-19 associated pulmonary aspergillosis) is an important complication of COVID-19. It has been reported that the incidence of CAPA is as high as 19%-33% worldwide. However, its onset has not been reported in Japan. A 72-year-old Japanese man was diagnosed with COVID-19 and was transferred to our hospital due to deterioration of respiratory condition. Treatment with remdesivir, dexamethasone (DEXA), and antibiotics was performed under mechanical ventilation. Although the condition improved temporarily, a new shadow appeared in the lung, and Aspergillus fumigatus was cultured from sputum. The patient was clinically diagnosed with CAPA and treated with voriconazole. However, his progress deteriorated and he died. High-risk COVID-19 patients should be tested for Aspergillus to ensure early diagnosis of CAPA.
    MeSH term(s) Aged ; Antifungal Agents/therapeutic use ; COVID-19/complications ; Fatal Outcome ; Humans ; Japan ; Male ; Pulmonary Aspergillosis/diagnosis ; Pulmonary Aspergillosis/drug therapy ; Respiration, Artificial
    Chemical Substances Antifungal Agents
    Language English
    Publishing date 2021-02-25
    Publishing country Netherlands
    Document type Case Reports
    ZDB-ID 1355399-9
    ISSN 1437-7780 ; 1341-321X
    ISSN (online) 1437-7780
    ISSN 1341-321X
    DOI 10.1016/j.jiac.2021.02.026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Autopsy Findings of Severe COVID-19 Pneumonia Combined with Pulmonary Aspergillosis, Pneumothorax, and Pulmonary Thromboembolisms.

    Kanaji, Nobuhiro / Kimura, Nachino / Kondo, Akihiro / Watanabe, Naoki / Inoue, Takuya / Mizoguchi, Hitoshi / Komori, Yuta / Kawada, Kosuke / Kadowaki, Norimitsu

    The American journal of case reports

    2023  Volume 24, Page(s) e939251

    Abstract: ... CASE REPORT A 64-year-old Japanese man was diagnosed with COVID-19. His past medical history included ... BACKGROUND COVID-19-associated pulmonary aspergillosis (CAPA), acute respiratory distress syndrome ... ARDS), pulmonary thromboembolism (PTE), and pneumothorax are complications in severe COVID-19 patients ...

    Abstract BACKGROUND COVID-19-associated pulmonary aspergillosis (CAPA), acute respiratory distress syndrome (ARDS), pulmonary thromboembolism (PTE), and pneumothorax are complications in severe COVID-19 patients. CASE REPORT A 64-year-old Japanese man was diagnosed with COVID-19. His past medical history included uncontrolled diabetes mellitus. He had no vaccination for COVID-19. Despite oxygen inhalation, remdesivir, dexamethasone (6.6 mg per day), and baricitinib (4 mg per day for 12 days), the disease progressed. The patient was supported with mechanical ventilation. Dexamethasone was switched to methylprednisolone (1000 mg per day for 3 days, and then reduced by half every 3 days), and intravenous heparin was initiated. Voriconazole (800 mg on the first day and then 400 mg per day for 14 days) was also started because Aspergillus fumigatus was detected in intratracheal sputum. However, he died of respiratory failure. Pathological findings of autopsy showed: (1) diffuse alveolar damage in a wide area of the lungs, which is consistent with ARDS due to COVID-19 pneumonia, (2) PTEs in peripheral pulmonary arteries, (3) CAPA, and (4) pneumothorax induced by CAPA. These conditions were all active states, suggesting that the treatments were insufficient. CONCLUSIONS Autopsy revealed active findings of ARDS, PTEs, and CAPA in a severe COVID-19 patient despite heavy treatment for each condition. CAPA can be a cause of pneumothorax. It is not easy to improve these conditions simultaneously because their treatments can induce antagonizing biological actions. To prevent severe COVID-19, it is important to reduce risk factors, such as by vaccination and appropriate blood glucose control.
    MeSH term(s) Male ; Humans ; Middle Aged ; Autopsy ; Pneumothorax ; COVID-19 ; Pulmonary Aspergillosis ; Respiratory Distress Syndrome ; Pulmonary Embolism ; Dexamethasone
    Chemical Substances Dexamethasone (7S5I7G3JQL)
    Language English
    Publishing date 2023-05-24
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2517183-5
    ISSN 1941-5923 ; 1941-5923
    ISSN (online) 1941-5923
    ISSN 1941-5923
    DOI 10.12659/AJCR.939251
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: COVID-19 associated pulmonary aspergillosis: a nationwide survey by the Japanese Respiratory Society.

    Takazono, Takahiro / Mukae, Hiroshi / Izumikawa, Koichi / Hasegawa, Naoki / Yokoyama, Akihito

    ERJ open research

    2021  Volume 7, Issue 4

    Abstract: ... associated pulmonary aspergillosis in critical COVID-19 cases was extremely low (0.54%) compared ... with those previously reported in the USA and Europe ... An online nationwide questionnaire survey in Japan revealed that the incidence rate of #COVID19 ...

    Abstract An online nationwide questionnaire survey in Japan revealed that the incidence rate of #COVID19 associated pulmonary aspergillosis in critical COVID-19 cases was extremely low (0.54%) compared with those previously reported in the USA and Europe
    Language English
    Publishing date 2021-10-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 2827830-6
    ISSN 2312-0541
    ISSN 2312-0541
    DOI 10.1183/23120541.00402-2021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top